Founded
in Lithuania.
Built for
the world.
200+
Research groups worldwide
20+
Institutional partnerships
150+
Instruments deployed
"It has been exciting to see Atrandi emerge as a leader in the development of high-throughput microfluidic technologies enabled by semi-permeable capsules for microbial single cell genomics. Leveraging top-tier talent, they are making transformative strides in enabling scientists to analyze the most fundamental units of biology at scales that were once unimaginable."
Ramunas Stepanauskas, PhD
Single Cell Genomics Center Director
"As an early adopter of the Flux device, I’ve witnessed first-hand the transformative impact of SPC technology on our approach to developing novel single-cell protocols. Semi-permeable capsules have become an indispensable component of our protocol development pipeline, offering unparalleled flexibility and efficiency that was previously unimaginable."
Christopher Cheshire, PhD
Head of Pipelines Technology at the Francis Crick Institute
"With the arrival of the microfluidic instrument Onyx, our custom single-cell workflows have taken a major leap forward in their sophistication, ease of deployment, and data quality. The Atrandi Bio team has provided superb training and support as we have migrated to their open-ended systems and protocols."
Daniel E. Wagner, PhD
Principal Investigator, Wagner Lab
"The SPC technology is a powerful platform for capturing cells, opening up new chemistry avenues by enabling full buffer exchanges, as well as eliminating challenges with cell or nuclei clumping or washing. These capabilities open up unique approaches for how we can capture single-cell genomic information for a variety of properties."
Andrew C. Adey, PhD
Professor | Principal Investigator, The Adey Lab
Leadership
The work requires deep scientific fluency. More than 70% of our team holds a scientific degree — because understanding the biology is a prerequisite for improving the tools.
Juozas
Nainys, PhD
Co-Founder &
Chief Executive Officer
Dalius
Jankevičius
Chief Finance
Officer
Sam
Ropp, PhD
Chief Commercial
Officer
Karolis
Leonavičius, PhD
Co-Founder & Chief
Technology Officer
Rapolas
Žilionis, PhD
Co-Founder &
Chief Scientific Officer
Emilis
Gegevičius
SVP Product
& Chief of Staff
Viktorija
Žepnickaitė
Director of
Production
Linas
Mažutis, PhD
Co-Founder &
Scientific Advisor
Atrandi
/ah-ˈtrɑːn-di/
"you discover" in Lithuanian
The Atrandi Story
Founded as Droplet Genomics in 2016, Atrandi grew from years spent at the intersection of engineering and biology – close enough to the limits of existing tools to understand exactly where they failed. Running multi-step workflows within droplets meant constant compromises between compatibility, control, and performance. Semi-Permeable Capsule technology was developed to solve that specific problem. By isolating single cells while allowing reagents to move freely, SPCs made it possible to run complex multi-step workflows under optimal conditions – something no existing system could do. What began as a technical solution became a new way to think about single-cell analysis entirely.
When the potential became clear, the decision was straightforward: this needed to exist beyond the lab. That instinct – to share, to enable, to build something that lets other scientists do work that wouldn’t otherwise be possible – is still the reason Atrandi exists. The company has grown, the platform has expanded, and the applications have multiplied. The most important discoveries are still ahead.
2016
Founded as Droplet Genomics
A team of scientists and engineers establishes Droplet Genomics – bringing together deep expertise in droplet microfluidics with a mission to transform how single-cell research is done.
2019
Onyx launched
The first Atrandi instrument enters the market, giving researchers precise control over droplet generation with real-time high-speed imaging for custom microfluidic workflows.
2020
Semi-Permeable Capsule technology published
The foundational Semi-Permeable Capsule (SPC) technology paper is published in collaboration with Vilnius University – establishing the scientific basis for a new class of single-cell analysis technology.
2021
Styx launched
A high-throughput droplet sorting platform designed for function-based screening – making applications like protein engineering, strain engineering, and others accessible at scale.
2022
Rebranded as Atrandi Biosciences
A new name to reflect a broader vision – enabling the full landscape of single-cell discovery.
2023
Global SPC rollout
SPC technology becomes globally accessible, empowering researchers to develop novel single-cell workflows beyond established methods.
Flux launched
SPC-powered single-cell encapsulation becomes accessible to any lab –no microfluidics expertise required, up to 100,000 cells in 30 minutes.
2024
Series A Closed
Atrandi closes a $25M Series A financing round with Lux Capital (USA), Vsquared (Germany), Practica Capital (Lithuania), Metaplanet (Estonia), and GRIDS Capital (Brazil) — accelerating commercial expansion into the US and deepening the product portfolio.
Mission
Empowering scientists to generate, interpret, and act on biological data at unprecedented depth and scale
The questions that matter most in biology require more than incremental gains. They demand more resolution, more cells, and more layers of information from the same experiment – and the freedom to design workflows around the biology, not around the platform.
Vision
Understanding biological complexity at the cellular level
The life sciences are entering a new era. The tools to answer questions that were unanswerable a generation ago are being built right now – and the data they generate is changing how we understand life at its most fundamental level. We are still at the beginning. The complexity of biology is not a barrier. It is the point.
Whether you want to collaborate, join us
or understand what SPC technology could do for your research – the conversation starts here.